<DOC>
	<DOCNO>NCT02633618</DOCNO>
	<brief_summary>A randomized , open-label , positive drug control ( Neurotropin , Japan organs Pharmaceutical Co. , Ltd. ) , multi-center study evaluate Analgecine 's efficacy safety treatment neuropathic pain .</brief_summary>
	<brief_title>Analgecine Treatment Neuropathic Pain</brief_title>
	<detailed_description>The study design evaluate efficacy safety Analgecine treatment neuropathic pain 2 week . It randomize , open-label , positive drug control , multi-center study phase III clinical trial . Patients recruit age 18 80 visual analysis scale ( VAS ) 3 8 . After randomization , subject divide 2 group : 1 ) Treatment Analgecine experiment group ; 2 ) Treatment Neurotropin positive control group . There 3 measurement time point day 0 , 7 , 14 treatment score patient pain VAS . The change VAS score day 14 compare group .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neurotropin</mesh_term>
	<criteria>1 . Patients establish medical record ; 2 . Patients age 18 year 80 year old . 3 . Patients neuropathic pain 4 . Patients childbearing age negative pregnancy test contraceptive measure ( oral injectable contraceptive ) take throughout course experiment 5 . Patients sign informed consent . 1 . Patients young 18 year old old 80 year old 2 . Patients dementia determine efficacy 3 . Patients pregnant , nursing may become pregnant study course take effective contraceptive measure . 4 . Patients history allergic reaction 5 . Patients suffer tuberculosis , cancer organic disease 6 . Patients alcoholics drug addict 7 . Others determine physician candidate clinical observation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>